Nestlé has introduced a new pre-meal beverage under its Boost brand designed to suppress hunger and promote the body’s natural production of the hormone GLP-1. The product, available on Amazon and select CVS stores, is positioned to appeal to consumers focusing on weight management.
The Boost pre-meal drink contains 10 grams of protein and just 45 calories per serving. Marketed as a hunger support nutritional shot, the product aims to complement the rising use of GLP-1 medications, which have gained popularity for their appetite-suppressing effects.
The growing demand for GLP-1 drugs like Ozempic and Wegovy is reshaping the food and beverage industry. Consumers using these medications often seek protein-rich foods, smaller portions, and hydration-supporting beverages, prompting companies to innovate their product lines.
Analysts project the global market for obesity drugs to reach $105 billion by 2030, signaling significant opportunities for food and beverage brands to align their offerings with evolving consumer habits.
Nestlé has been proactive in this space, recently launching Vital Pursuit, its first major U.S. brand in nearly three decades. The product line includes pizzas, sandwiches, and bowls tailored to individuals focusing on weight management, with an emphasis on convenience, balanced nutrition, and portion control.
Other major food companies are also tapping into the GLP-1 trend. Conagra Brands announced plans to label over two dozen Healthy Choice products as “GLP-1 friendly,” highlighting their high protein, low-calorie, and fiber-rich content.
As the weight management landscape continues to evolve, brands are increasingly aligning their portfolios with the changing dietary needs of consumers using GLP-1 medications.